Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D

Published:2022-06-15 Issue:S1 Volume:13 Page:35-49
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

González-Albarrán Olga,Morales Cristóbal,Pérez-Maraver Manuel,Aparicio-Sánchez José Juan,Simó Rafael

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-022-01276-2.pdf

Reference62 articles.

1. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104–12.

2. Kramer CK, Zinman B. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type 2 diabetes. Annu Rev Med. 2019;70:323–34.

3. van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41:1543–56.

4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new perspective on proteinuria and drug therapy for diabetic kidney disease;Frontiers in Pharmacology;2024-07-31

2. Biotransformation and disposition characteristics of HSK7653, a novel long‐acting dipeptidyl peptidase‐4 inhibitor for the treatment of type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-22

3. Combined effects of sodium-glucose cotransporter 2 inhibitor and angiotensin receptor-neprilysin inhibitor on renal function in cardiovascular disease patients with type 2 diabetes mellitus: a retrospective cohort study;Frontiers in Endocrinology;2024-01-11

4. Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy;Pharmaceuticals;2023-09-05

5. GLP-1 receptor agonists and SGLT2 inhibitors: The need to shed light on their safety risks real dimension and possible mechanisms;Journal of Diabetes and its Complications;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3